Gocovri (amantadine) extended release capsules, from Adamas Pharmaceuticals, are used for treatment of dyskinesia (involuntary movement disorders) in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Dyskinesia is often a side effect of levodopa-based Parkinson's disease treatment. Approved in August 2017, it is the first medicine for the treatment of dyskinesia in Parkinson's disease patients.
Subscribe to receive email notifications whenever new articles are published.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex® (updated Oct 1st, 2018), Cerner Multum™ (updated Oct 2nd, 2018), Wolters Kluwer™ (updated Oct 2nd, 2018) and others. To view content sources and attributions, please refer to our editorial policy.